Top ▲

Liver X receptor-β

Click here for help

Target id: 601

Nomenclature: Liver X receptor-β

Systematic Nomenclature: NR1H2

Family: 1H. Liver X receptor-like receptors

Gene and Protein Information Click here for help
Species AA Chromosomal Location Gene Symbol Gene Name Reference
Human 460 19q13.3 NR1H2 nuclear receptor subfamily 1 group H member 2 36
Mouse 446 7 B3 Nr1h2 nuclear receptor subfamily 1, group H, member 2 35
Rat 446 1q22 Nr1h2 nuclear receptor subfamily 1, group H, member 2 37
Previous and Unofficial Names Click here for help
NER | NER-I | LXRβ | Oxysterols receptor β | ubiquitously-expressed nuclear receptor | liver X receptor beta | nuclear orphan receptor LXR-beta | orphan nuclear receptor OR-1 | oxysterols receptor LXR-beta | RIP15 | UNR | nuclear receptor subfamily 1
Database Links Click here for help
Alphafold
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  LXR-beta ligand binding domain
PDB Id:  1UPV
Ligand:  T0901317
Resolution:  2.1Å
Species:  Human
References:  13
Natural/Endogenous Ligands Click here for help
24(S), 25-epoxycholesterol
24(S)-hydroxycholesterol
27-hydroxycholesterol
22R-hydroxycholesterol
Comments: A series of oxysterols are natural ligands
Potency order (Human)
20S-hydroxycholesterol, 22R-hydroxycholesterol, 24(S)-hydroxycholesterol > 25-hydroxycholesterol, 27-hydroxycholesterol  [21]

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
L-783483 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.2 pKd 27
pKd 8.2 [27]
AZ12260493 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Agonist 8.0 pKi 2
pKi 8.0 (Ki 1.1x10-8 M) [2]
desmosterol Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 5.8 pKi 43
pKi 5.8 (Ki 1.4x10-6 M) [43]
acetyl-podocarpic dimer Small molecule or natural product Click here for species-specific activity table Hs Agonist 9.0 pEC50 38
pEC50 9.0 [38]
GW3965 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 7.5 pEC50 5
pEC50 7.5 [5]
T0901317 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 7.3 pEC50 34
pEC50 7.3 [34]
27-hydroxycholesterol Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Hs Agonist 7.2 pEC50 10
pEC50 7.2 [10]
IMB-808 Small molecule or natural product Click here for species-specific activity table Hs Partial agonist 6.3 pEC50 22
pEC50 6.3 (EC50 5.3x10-7 M) [22]
Description: In a LXRβ-GAL4 luciferase reporter assay using transfected HEK293T cells.
24(S), 25-epoxycholesterol Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Agonist 5.5 – 7.0 pEC50 21,39
pEC50 5.5 – 7.0 [21,39]
rovazolac Small molecule or natural product Immunopharmacology Ligand Hs Agonist >6.0 pEC50 28
pEC50 >6.0 (EC50 <1x10-6 M) [28]
Description: Binned data point measured in a luciferase transactivation assay in HEK293 cells expressing the hLXRβ ligand binding domain (aa 153-461)
22R-hydroxycholesterol Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Agonist 5.5 pEC50 16
pEC50 5.5 [16]
24(S)-hydroxycholesterol Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Hs Agonist 5.5 pEC50 21
pEC50 5.5 [21]
Agonist Comments
Other endogenous agonist include cholic acid [39].
Antagonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
GSK2033 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.5 pIC50 45
pIC50 7.5 [45]
SR9238 Small molecule or natural product Click here for species-specific activity table Mm Inverse agonist 7.4 pIC50 12
pIC50 7.4 (IC50 4.3x10-8 M) [12]
compound 17l [PMID: 26288691] Small molecule or natural product Immunopharmacology Ligand Hs Antagonist 5.7 pIC50 29
pIC50 5.7 (IC50 1.8x10-6 M) [29]
Description: Binding affinity to LXRβ ligand binding domain by TR-FRET assay.
View species-specific antagonist tables
Antagonist Comments
Inverse agonist SR9243 induces interaction between Liver-X receptors and their corepressors, resulting in an inhibition of aerobic glycolysis and lipogenesis [9].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
GSK9772 Small molecule or natural product Hs Negative 7.5 pIC50 4
pIC50 7.5 (IC50 3x10-8 M) [4]
Immunopharmacology Comments
Liver X receptors are involved in the regulation of lipid metabolism and inflammatory responses. LXRs are drug targets for cholesterol homeostasis (hypercholesterolaemia), inflammation, and with therapeutic potential in neurodegenerative diseases [42]. Vitae Pharmaceuticals/Allergan had their selective LXRβ agonist VTP-38543 (structure not disclosed) in Phase 2 trial as a topically applied atopic dermatitis candidate [7] (NCT02655679). The VTP-38543 programme was terminated due to (unreported) safety issues that were identified in Phase 2.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Antigen presentation
Immuno Process:  Immune regulation
Immuno Process:  Cytokine production & signalling
DNA Binding Click here for help
Structure:  RXR partner
HRE core sequence:  AGGTCANNNNAGGTCA
Response element:  DR1
DNA Binding Comments
RXR binds the 5’ hexamer while LXR binds the 3’ hexamer of DR4s. LXR/RXR heterodimer is reported to also bind DR1s in reverse orientation.
Co-binding Partners Click here for help
Name Interaction Effect Reference
Retinoid X receptor-α Physical 35
SHP Physical, Functional 3
Main Co-regulators Click here for help
Name Activity Specific Ligand dependent AF-2 dependent Comments References
NCOA1 Co-activator No Yes No 30
EP300 Co-activator No Yes No 15
NCOR1 Co-activator No Yes No 14
NCOR2 None No Yes No 14
Main Target Genes Click here for help
Name Species Effect Technique Comments References
VEGFA Human Activated Angiogenesis and neovascularization 41
ABCA1 Human Activated Transient transfection, EMSA Reverse cholesterol transport efflux 6,33
NR1H3 Human Activated Transient transfection, EMSA 19
CPOC1 Human Activated Transient transfection 26
APOC2 Human Activated Transient transfection 26
APOC4 Human Activated Transient transfection 26
CETP Human Activated Transient transfection, EMSA 25
ABCG1 Human Activated Transient transfection, EMSA Reverse cholesterol transport efflux 18,40
SREBF1 Human Activated Transient transfection, EMSA Fatty acid and triglycerides synthesis 32
SLC2A4 Human Activated Transient transfection, EMSA Insulin stimulated glucose uptake 8
FASN Human Activated Transient transfection, EMSA Fatty acid synthesis 17
Abcg8 Mouse Activated Intestinal cholesterol efflux 31
Npc1l1 Mouse Repressed Intestinal cholesterol absorption 23
APOE Human Activated Transient transfection, EMSA Cholesterol transport 20
Scd1 Mouse Activated Unsaturated fatty acid synthesis
CYP7A1 Human Activated Cholesterol to bile acid conversion
Abcg5 Mouse Activated Intestinal cholesterol efflux 31
Mylip Mouse Activated Induce lipoprotein receptor (LDLR) degradation, the receptor responsible for cholesterol uptake 44
Tissue Distribution Click here for help
Ubiquitous
Species:  Rat
Technique:  Northern Blot
References:  24,37
Physiological Consequences of Altering Gene Expression Click here for help
LXRβ knock-out mice
Species:  Mouse
Tissue: 
Technique:  Knock-out
References:  1,11
Physiological Consequences of Altering Gene Expression Comments
Normal resistance to dietary cholesterol, unlike the LXRα KO. LXRβ KO mice are also reported to show alterations in adipocyte growth, glucose homeostasis and beta cell function.
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0002182 abnormal astrocyte morphology PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0009278 abnormal bone marrow cell physiology PMID: 12193651 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0010152 abnormal brain ependyma morphology PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0004950 abnormal brain vasculature morphology PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0000822 abnormal brain ventricle morphology PMID: 12368482 
Nr1h2tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352463  MP:0003191 abnormal cellular cholesterol metabolism PMID: 11238557 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0005537 abnormal cerebral aqueduct morphology PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0005278 abnormal cholesterol homeostasis PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0000820 abnormal choroid plexus morphology PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0001119 abnormal female reproductive system morphology PMID: 17166844 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0003699 abnormal female reproductive system physiology PMID: 17166844 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0000828 abnormal fourth ventricle morphology PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0000823 abnormal lateral ventricle morphology PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002786 abnormal Leydig cell morphology PMID: 17341595 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0002118 abnormal lipid homeostasis PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002446 abnormal macrophage morphology PMID: 12193651 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0001145 abnormal male reproductive system morphology PMID: 17166844 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0003698 abnormal male reproductive system physiology PMID: 17166844 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0009229 abnormal median eminence morphology PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0000920 abnormal myelination PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0003871 abnormal myelin sheath morphology PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0008256 abnormal myometrium morphology PMID: 17166844 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0008256 abnormal myometrium morphology PMID: 17166844 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002907 abnormal parturition PMID: 17166844 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0002907 abnormal parturition PMID: 17166844 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002216 abnormal seminiferous tubule morphology PMID: 17341595 
Nr1h2+|Nr1h2tm1.1Gstr|Rxrb+|Rxrbtm1Mma Nr1h2tm1.1Gstr/Nr1h2+,Rxrbtm1Mma/Rxrb+
involves: 129 * C57BL/6
MGI:1352463  MGI:98215  MP:0002784 abnormal Sertoli cell morphology PMID: 14993927 
Nr1h2tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr
involves: 129 * C57BL/6
MGI:1352463  MP:0002784 abnormal Sertoli cell morphology PMID: 14993927 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002784 abnormal Sertoli cell morphology PMID: 17341595 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0002784 abnormal Sertoli cell morphology PMID: 17341595 
Nr1h2tm1Dgen Nr1h2tm1Dgen/Nr1h2tm1Dgen
B6.129-Nr1h2
MGI:1352463  MP:0001533 abnormal skeleton physiology PMID: 20133709 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002685 abnormal spermatogonia proliferation PMID: 17341595 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0002685 abnormal spermatogonia proliferation PMID: 17341595 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0009688 abnormal spinal cord central canal morphology PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0000836 abnormal substantia nigra morphology PMID: 12368482 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0000826 abnormal third ventricle morphology PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0009671 abnormal uterus physiology PMID: 17166844 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0009671 abnormal uterus physiology PMID: 17166844 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0008934 absent choroid plexus PMID: 12368482 
Nr1h2tm1Djm|Tg(APPswe,PSEN1dE9)85Dbo Nr1h2tm1Djm/Nr1h2tm1Djm,Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129/Sv * C3H * C57BL/6
MGI:1352463  MGI:3525178  MP:0003329 amyloid beta deposits PMID: 17563384 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0003354 astrocytosis PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002773 decreased circulating luteinizing hormone level PMID: 17341595 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002780 decreased circulating testosterone level PMID: 17341595 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0008948 decreased neuron number PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0004852 decreased testis weight PMID: 17341595 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0000755 hindlimb paralysis PMID: 17166844 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0000755 hindlimb paralysis PMID: 17166844 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0000740 impaired smooth muscle contractility PMID: 17166844 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0000740 impaired smooth muscle contractility PMID: 17166844 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac
MGI:1352462  MGI:1352463  MP:0010027 increased liver cholesterol level PMID: 10968783 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0004778 increased macrophage derived foam cell number PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0009763 increased sensitivity to induced morbidity/mortality PMID: 12524534 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0009763 increased sensitivity to induced morbidity/mortality PMID: 12524534 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0002412 increased susceptibility to bacterial infection PMID: 12524534 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0002412 increased susceptibility to bacterial infection PMID: 12524534 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0001915 intracranial hemorrhage PMID: 12368482 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0008280 male germ cell apoptosis PMID: 17341595 
Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr,Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352462  MGI:1352463  MP:0003224 neuron degeneration PMID: 12368482 
Nr1h2tm1Gstr Nr1h2tm1Gstr/Nr1h2tm1Gstr
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:1352463  MP:0002169 no abnormal phenotype detected PMID: 11238557 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0008028 pregnancy-related premature death PMID: 17166844 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
involves: 129/Sv * C57BL/6
MGI:1352463  MP:0008028 pregnancy-related premature death PMID: 17166844 
Npc1m1N|Nr1h2tm1Djm Npc1m1N/Npc1m1N,Nr1h2tm1Djm/Nr1h2tm1Djm
involves: BALB/c
MGI:1097712  MGI:1352463  MP:0002083 premature death PMID: 18160655 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0001922 reduced male fertility PMID: 17341595 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0001154 seminiferous tubule degeneration PMID: 17341595 
Nr1h2tm1Djm|Nr1h3tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm,Nr1h3tm1Djm/Nr1h3tm1Djm
involves: 129S6/SvEvTac * C57BL/6
MGI:1352462  MGI:1352463  MP:0003205 testicular atrophy PMID: 17341595 
Nr1h2tm1Djm Nr1h2tm1Djm/Nr1h2tm1Djm
Not Specified
MGI:1352463  MP:0001218 thin epidermis PMID: 11851872 

References

Show »

1. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Björkhem I, Pettersson S, Gustafsson JA. (2001) Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest, 107 (5): 565-73. [PMID:11238557]

2. AstraZeneca. AZD9291. Accessed on 12/09/2014. Modified on 12/09/2014. astrazeneca.com, http://openinnovation.astrazeneca.com/what-we-offer/compound/azd9291/

3. Brendel C, Schoonjans K, Botrugno OA, Treuter E, Auwerx J. (2002) The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol, 16 (9): 2065-76. [PMID:12198243]

4. Chao EY, Caravella JA, Watson MA, Campobasso N, Ghisletti S, Billin AN, Galardi C, Wang P, Laffitte BA, Iannone MA et al.. (2008) Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem, 51 (18): 5758-65. [PMID:18800767]

5. Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM. (2002) Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem, 45 (10): 1963-6. [PMID:11985463]

6. Costet P, Luo Y, Wang N, Tall AR. (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem, 275 (36): 28240-5. [PMID:10858438]

7. Czarnowicki T, Dohlman AB, Malik K, Antonini D, Bissonnette R, Chan TC, Zhou L, Wen HC, Estrada Y, Xu H et al.. (2018) Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial. Ann Allergy Asthma Immunol, 120 (6): 631-640.e11. [PMID:29567358]

8. Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI. (2003) Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha. J Biol Chem, 278 (48): 48283-91. [PMID:12970362]

9. Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM et al.. (2015) Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell, 28 (1): 42-56. [PMID:26120082]

10. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG. (2001) 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem, 276 (42): 38378-87. [PMID:11504730]

11. Gerin I, Dolinsky VW, Shackman JG, Kennedy RT, Chiang SH, Burant CF, Steffensen KR, Gustafsson JA, MacDougald OA. (2005) LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem, 280 (24): 23024-31. [PMID:15831500]

12. Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP. (2013) A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol, 8 (3): 559-67. [PMID:23237488]

13. Hoerer S, Schmid A, Heckel A, Budzinski RM, Nar H. (2003) Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J Mol Biol, 334 (5): 853-61. [PMID:14643652]

14. Hu X, Li S, Wu J, Xia C, Lala DS. (2003) Liver X receptors interact with corepressors to regulate gene expression. Mol Endocrinol, 17 (6): 1019-26. [PMID:12663743]

15. Huuskonen J, Fielding PE, Fielding CJ. (2004) Role of p160 coactivator complex in the activation of liver X receptor. Arterioscler Thromb Vasc Biol, 24 (4): 703-8. [PMID:14764426]

16. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature, 383 (6602): 728-31. [PMID:8878485]

17. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne TF, Tontonoz P. (2002) Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem, 277 (13): 11019-25. [PMID:11790787]

18. Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, Edwards PA. (2001) Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J Biol Chem, 276 (42): 39438-47. [PMID:11500512]

19. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P. (2001) Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol, 21 (22): 7558-68. [PMID:11604492]

20. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. (2001) LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA, 98 (2): 507-12. [PMID:11149950]

21. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. (1997) Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem, 272 (6): 3137-40. [PMID:9013544]

22. Li N, Wang X, Xu Y, Lin Y, Zhu N, Liu P, Lu D, Si S. (2017) Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. Mol Pharmacol, 91 (4): 264-276. [PMID:28087808]

23. Lo Sasso G, Murzilli S, Salvatore L, D'Errico I, Petruzzelli M, Conca P, Jiang ZY, Calabresi L, Parini P, Moschetta A. (2010) Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab, 12 (2): 187-93. [PMID:20674863]

24. Lu TT, Repa JJ, Mangelsdorf DJ. (2001) Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem, 276 (41): 37735-8. [PMID:11459853]

25. Luo Y, Tall AR. (2000) Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest, 105 (4): 513-20. [PMID:10683381]

26. Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, Tontonoz P, Edwards PA. (2002) Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem, 277 (35): 31900-8. [PMID:12032151]

27. Menke JG, Macnaul KL, Hayes NS, Baffic J, Chao YS, Elbrecht A, Kelly LJ, Lam MH, Schmidt A, Sahoo S, Wang J, Wright SD, Xin P, Zhou G, Moller DE, Sparrow CP. (2002) A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology, 143 (7): 2548-58. [PMID:12072387]

28. Mohan R. (2013) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions. Patent number: WO2013130892. Assignee: Anayaderm, Inc. Priority date: 02/03/2012. Publication date: 06/09/2013.

29. Nomura S, Endo-Umeda K, Aoyama A, Makishima M, Hashimoto Y, Ishikawa M. (2015) Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators. ACS Med Chem Lett, 6 (8): 902-7. [PMID:26288691]

30. Otte K, Kranz H, Kober I, Thompson P, Hoefer M, Haubold B, Remmel B, Voss H, Kaiser C, Albers M, Cheruvallath Z, Jackson D, Casari G, Koegl M, Pääbo S, Mous J, Kremoser C, Deuschle U. (2003) Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol, 23 (3): 864-72. [PMID:12529392]

31. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. (2002) Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem, 277 (21): 18793-800. [PMID:11901146]

32. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. (2000) Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev, 14 (22): 2819-30. [PMID:11090130]

33. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science, 289 (5484): 1524-9. [PMID:10968783]

34. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. (2000) Role of LXRs in control of lipogenesis. Genes Dev, 14 (22): 2831-8. [PMID:11090131]

35. Seol W, Choi HS, Moore DD. (1995) Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol, 9 (1): 72-85. [PMID:7760852]

36. Shinar DM, Endo N, Rutledge SJ, Vogel R, Rodan GA, Schmidt A. (1994) NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene, 147 (2): 273-6. [PMID:7926814]

37. Song C, Kokontis JM, Hiipakka RA, Liao S. (1994) Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc Natl Acad Sci USA, 91 (23): 10809-13. [PMID:7971966]

38. Sparrow CP, Baffic J, Lam MH, Lund EG, Adams AD, Fu X, Hayes N, Jones AB, Macnaul KL, Ondeyka J, Singh S, Wang J, Zhou G, Moller DE, Wright SD, Menke JG. (2002) A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem, 277 (12): 10021-7. [PMID:11790770]

39. Theofilopoulos S, Wang Y, Kitambi SS, Sacchetti P, Sousa KM, Bodin K, Kirk J, Saltó C, Gustafsson M, Toledo EM et al.. (2013) Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol, 9 (2): 126-33. [PMID:23292650]

40. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. (2000) Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem, 275 (19): 14700-7. [PMID:10799558]

41. Walczak R, Joseph SB, Laffitte BA, Castrillo A, Pei L, Tontonoz P. (2004) Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors. J Biol Chem, 279 (11): 9905-11. [PMID:14699103]

42. Xu P, Li D, Tang X, Bao X, Huang J, Tang Y, Yang Y, Xu H, Fan X. (2013) LXR agonists: new potential therapeutic drug for neurodegenerative diseases. Mol Neurobiol, 48 (3): 715-28. [PMID:23625315]

43. Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF, Mangelsdorf DJ, Cohen JC et al.. (2006) Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem, 281 (38): 27816-26. [PMID:16857673]

44. Zelcer N, Hong C, Boyadjian R, Tontonoz P. (2009) LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science, 325 (5936): 100-4. [PMID:19520913]

45. Zuercher WJ, Buckholz RG, Campobasso N, Collins JL, Galardi CM, Gampe RT, Hyatt SM, Merrihew SL, Moore JT, Oplinger JA et al.. (2010) Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem, 53 (8): 3412-6. [PMID:20345102]

Contributors

Show »

How to cite this page